NetworkNewsBreaks – Lexaria Bioscience Corp. (CS
Post# of 721
Biotechnology company and drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTC: LXRP) on Wednesday announced that work has commenced on its largest-ever cannabinoid research program, which will also test Lexaria-designed nanotech enhancements. According to the update, the new program is comprised of 11 separate animal studies, each comparable in scope to individual animal studies the company conducted during 2018. Six months ago, Lexaria began its 2019 in vivo study design. All laboratory test articles have been produced and exceed all required quality control thresholds, and the project has now advanced to the implementation stage. The 2019 R&D project is the largest undertaken in Lexaria’s history and will test DehydraTECH(TM) delivery technology, which has already evidenced industry-leading performance, for a variety of potential performance enhancing variations.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer